Based on the Compass Therapeutics Inc. stock forecast from 2 analysts, the average analyst target price for Compass Therapeutics Inc. is USD 9.00 over the next 12 months. Compass Therapeutics Inc.’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Compass Therapeutics Inc. is Very Bearish, which is based on 0 positive signals and 2 negative signals. At the last closing, Compass Therapeutics Inc.’s stock price was USD 1.49. Compass Therapeutics Inc.’s stock price has changed by -5.70% over the past week, -30.05% over the past month and -48.80% over the last year.
No recent analyst target price found for Compass Therapeutics Inc.
No recent average analyst rating found for Compass Therapeutics Inc.
Company Overview Compass Therapeutics Inc.
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts. Read Less
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that block...Read More
Frequently Asked Questions About Compass Therapeutics Inc. (CMPX) Stock
Based on ratings from 2 analysts Compass Therapeutics Inc.'s stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 2 buy, sell and hold ratings.
Unfortunately we do not have enough data on CMPX's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for CMPX is USD 9.00 over the next 12 months. The maximum analyst target price is USD 10 while the minimum anlayst target price is USD 8.
Unfortunately we do not have enough data on CMPX's stock to indicate if its overvalued.
The last closing price of CMPX's stock was USD 1.49.
The most recent market capitalization for CMPX is USD 0.20B.
Based on targets from 2 analysts, the average taret price for CMPX is projected at USD 9.00 over the next 12 months.
This means that CMPX's stock price may go up by +504.03% over the next 12 months.
We can't find any ETFs which contains Compass Therapeutics Inc.'s stock.
As per our most recent records Compass Therapeutics Inc. has 32 Employees.
Compass Therapeutics Inc.'s registered address is 80 Guest Street, Boston, MA, United States, 02135.
You can get more information about it from Compass Therapeutics Inc.'s website at https://www.compasstherapeutics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for CMPX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
